MHRA OKs Celltrion’s Phase I trial of COVID drug
The trial will enrol patients with mild symptoms of SARS-CoV-2 infection to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59
Read More
Tag: CT-P59
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
